Replimune Says Tudrakev Accounts Could Double By Year-End, With Some Hospitals Skipping Formulary Review

The cancer drugmaker's executives described a fast first three weeks and a nearly fully staffed sales team.

Share
Replimune Says Tudrakev Accounts Could Double By Year-End, With Some Hospitals Skipping Formulary Review

Replimune, the clinical-stage biotech behind the melanoma therapy Tudrakev, said on its earnings call Wednesday that closer to 20 accounts have ordered the drug and begun treating patients, and that the number could roughly double by the end of the year. Chief Commercial Officer Michelle DiNapoli said some hospitals are bypassing their usual formulary review, the vetting that decides which drugs a hospital stocks, to get it faster.

A launch funnel, in numbers

DiNapoli told analysts that by the end of the year "we could sort of double" the accounts already treating patients, with several more facilities expected to clear formulary in November. Other sites, she said, are "expediting and in some cases bypassing" the formulary review, which she cited as proof of unmet need.

She laid out the launch as a funnel. Proactive engagement has reached more than 70% of the initial 200 target accounts, about 20 accounts have placed the drug on formulary, and as of Friday over 15 institutions had written at least one prescription. Moffitt and Memorial Sloan Kettering are among the high-volume centers that moved quickly.

CEO Sushil Patel said the launch is "going very, very well." He said a broad label with no requirement for prior BRAF-targeted therapy lets physicians treat patients progressing on PD-1 therapy, and that the company holds more than a year of inventory made at its own facility.

Sales team nearly built

Asked by a JPMorgan analyst about the sales force, DiNapoli said 23 account management positions are filled. Patel said only a couple of internal hires remain.

A Jefferies analyst asked whether the next wave of 250 accounts, which DiNapoli said would represent another 20% of melanoma patients, could be reached sooner. Patel said Replimune will move when it is ready and has fully penetrated the first 200 accounts.

DiNapoli said Replimune expects a permanent J-code, the billing code for the drug, by April 2027. Replimune has no revenue yet, since first commercial shipments occurred in early October; the list price is $450,000 per course of therapy before rebates and discounts, and the company is not giving revenue guidance.

Cash and the company

Replimune develops oncolytic immunotherapies, engineered herpes viruses injected into tumors to kill cancer and provoke an immune attack. Tudrakev is its first commercial product.

Chief Financial Officer Emily Hill said the company ended the September quarter with $307.8 million in cash, including $141 million in net proceeds from an August offering, versus $195.3 million at June 30. Net loss was $57.1 million, down from $69.8 million in the prior quarter. Management expects the cash to fund operations for more than 12 months. The company's market value was about $1.2 billion in Wednesday morning trading.

Patel said Replimune's uveal melanoma study and its confirmatory melanoma study, now open to more European sites, are both enrolling very well.

Sources

More on Replimune Group

All Replimune Group (REPL) coverage →